Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 01, 2016 07:00 ET | Source: Apricus Biosciences

Apricus Biosciences Announces Corporate Update and Second Quarter 2016 Financial Results Conference Call

SAN DIEGO, Aug. 01, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that...
July 27, 2016 07:00 ET | Source: Apricus Biosciences

Apricus Biosciences Announces Approval of Vitaros(R) for the Treatment of Erectile Dysfunction in Lebanon

SAN DIEGO, July 27, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that...
July 25, 2016 07:00 ET | Source: Apricus Biosciences

Apricus Biosciences Further Expands Existing Vitaros® Partnership with Ferring Pharmaceuticals in Europe and Asia

Apricus Eligible to Receive an Additional $3.6 Million in Upfront and Pre-Commercialization Milestone Payments for the Expanded Territory Apricus and Sandoz Agree to Mutually Terminate...
July 06, 2016 08:00 ET | Source: Apricus Biosciences

Apricus Biosciences Enters Into Common Stock Purchase Agreement With Aspire Capital

SAN DIEGO, July 06, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI) (the “Company” or “Apricus”), a biopharmaceutical company focusing on the development and commercialization of...
May 09, 2016 07:00 ET | Source: Seelos Therapeutics, Inc.

Apricus Biosciences Provides Corporate Update and First Quarter Financial Results

SAN DIEGO, May 09, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today reported financial...
May 03, 2016 14:36 ET | Source: Seelos Therapeutics, Inc.

CORRECTING and REPLACING -- Apricus Biosciences to Host Live Webcast KOL Event on May 9th Addressing Vitaros® and Erectile Dysfunction Population

In a release issued under the same headline earlier today by Apricus Biosciences, Inc. (Nasdaq:APRI), please note that in the second line of the subhead of the release, "2H 2016" should...
May 03, 2016 07:01 ET | Source: Seelos Therapeutics, Inc.

Apricus Biosciences to Host Live Webcast KOL Event on May 9th Addressing Vitaros® and Erectile Dysfunction Population

Presentation Speaker will be Edward D. Kim, M.D., Professor, The University of Tennessee Graduate School of Medicine Vitaros U.S. NDA Re-Submission Remains on Schedule for 2H 2016 SAN DIEGO, May ...
May 03, 2016 07:00 ET | Source: Seelos Therapeutics, Inc.

Apricus Biosciences to Announce Corporate Update and First Quarter 2016 Financial Results

SAN DIEGO, May 03, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that...
April 06, 2016 07:00 ET | Source: Seelos Therapeutics, Inc.

Apricus Biosciences Updates Strategic Corporate Objectives

Company to Focus on Vitaros® Revenue Growth, U.S. NDA Re-Submission and Additional Commercial Launches in Europe, Latin America and the Middle East Company Announces a 30% Reduction in Staff and...
March 28, 2016 07:00 ET | Source: Seelos Therapeutics, Inc.

Apricus Reports Top-Line Phase 2b Data for Fispemifene in Symptomatic Secondary Hypogonadism

Fispemifene Failed to Achieve Statistical Significance in Key Clinical Benefit Endpoints Despite Increase in Testosterone Levels Company Will Focus on Internal Pipeline, Including Expanding Market...